Table 3 Characteristics of 32 NSCLC patients with pre- and post-T-SPOT testing
Characteristics | N = 32 | (%) | |
|---|---|---|---|
Age, years | |||
<65 | 19 | 59.4 | |
≥ 65 | 13 | 40.6 | |
Sex | |||
Male | 30 | 93.8 | |
Female | 2 | 6.2 | |
ECOG-PS | |||
0 | 16 | 50.0 | |
1 | 16 | 50.0 | |
Histopathology | |||
Adenocarcinoma | 15 | 46.9 | |
Squamous cell carcinoma | 15 | 46.9 | |
Other | 2 | 6.2 | |
TNM | |||
Stage-III | 11 | 34.4 | |
Stage-IV | 21 | 65.6 | |
ICIs | Pembrolizumab | 5 | 15.6 |
Tislelizumab | 14 | 43.8 | |
Camrelizumab | 5 | 15.6 | |
Sintilimab | 8 | 25.0 | |
ICIs lines | First line | 24 | 75.0 |
Second line | 8 | 25.0 | |
Metastasis | |||
Barin | 7 | 21.9 | |
Bone | 9 | 28.1 | |
Liver | 2 | 6.4 | |
Driver genes | Positive | 10 | 31.2 |
Targeted therapy | 3 | 9.4 |